RLMD News and Press, Relmada Therapeutics Inc. From 11/08/23

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results PR Newswire CORAL GABLES, Fla. , Nov. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ...

Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 PR Newswire CORAL GABLES, Fla. , Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology compan...

2023-10-13 19:50:09 ET Summary Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying efficacy appears robust, consistently reporting treatment responses comparable to approved antidepressa...

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 PR Newswire Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and b...

Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit PR Newswire CORAL GABLES, Fla. , Oct. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ner...

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress PR Newswire CORAL GABLES, Fla. , Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-...

2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...

2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...

2023-09-21 08:26:58 ET Losers: Travere Therapeutics ( TVTX ) -34% announces confirmatory data from the phase 3 PROTECT study of FILSPARI demonstrating long-term kidney function. Avinger ( AVGR ) -15% . Relmada Therapeutics ( RLMD ) -9% . Sibanye...

2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si  ( QSI ) +5% . Losers: Vahanna Tech ...